Karyopharm Therapeutics (KPTI) Common Equity (2012 - 2025)

Karyopharm Therapeutics has reported Common Equity for 14 years, with the latest figure at -$292.9 million in Q4 2025.

• For the quarter ending Q4 2025, Common Equity fell 57.47% year-over-year to -$292.9 million; the trailing twelve-month figure through Dec 2025 stood at -$292.9 million (down 57.47% YoY), and the FY2025 full-year result was -$292.9 million, down 57.47% from the prior year.
• Common Equity for Q4 2025 stood at -$292.9 million, down from -$269.3 million in the prior quarter.
• The five-year high for Common Equity was -$16.7 million in Q4 2022, with the low at -$292.9 million in Q4 2025.
• Historically, Common Equity has averaged -$134.6 million across 5 years, with a median of -$129.1 million in 2021.
• Annual changes were most pronounced in 2022 — Common Equity surged 79.09% — and 2023, when it plunged 717.76%.
• Karyopharm Therapeutics' Common Equity stood at -$79.7 million in 2021, then surged by 79.09% to -$16.7 million in 2022, then sank by 717.76% to -$136.2 million in 2023, then tumbled by 36.57% to -$186.0 million in 2024, then slumped by 57.47% to -$292.9 million in 2025.
• The last three Common Equity figures came in at -$292.9 million (Q4 2025), -$269.3 million (Q3 2025), and -$238.9 million (Q2 2025), per Business Quant data.